Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Cohen

Pain Medicine Chicago, IL Medical Doctor

NPI 1578515482 CMS profile 25429

259 E Erie St Ste 1400, Chicago, IL 60611

Open in the dashboard

General payments

$216,879

109 records reported · program years 2019–2025

Research payments

$1,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$75,513 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Steven Cohen of Chicago, IL is reported in the CMS Open Payments database as having received $216,879 across 109 general payments and $1,500 in research payments paid to them. Separately, studies naming them as principal investigator received $75,513 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,979 42
2024 General $34,710 23
2023 General $39,549 20
2022 General $52,357 12
2021 General $11,050 3
2020 General $11,975 4
2020 Research $1,500 1
2019 General $15,260 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Cohen
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Steven Cohen were reported at $51,979. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Steven Cohen Pain Medicine median Middle half National median
2019 $15,260 $498 $126–$1,682 $163
2020 $11,975 $284 $80–$910 $114
2021 $11,050 $399 $112–$1,219 $132
2022 $52,357 $455 $137–$1,484 $149
2023 $39,549 $484 $128–$1,495 $160
2024 $34,710 $498 $131–$1,540 $164
2025 $51,979 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SPR Therapeutics, Inc $73,380 27 payments
  2. Scilex Pharmaceuticals Inc. $61,025 10 payments
  3. Avanos Medical $36,929 9 payments
  4. Merck Sharp & Dohme Corporation $14,691 18 payments
  5. Vertex Pharmaceuticals Incorporated $13,285 8 payments
  6. AbbVie, Inc. $9,564 9 payments
  7. GRT US Holding, Inc. $5,860 5 payments
  8. Stratus Medical, LLC $682 11 payments
  9. Abbott Laboratories $593 2 payments
  10. Medtronic, Inc. $360 3 payments
  11. Other $510 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $163,361 37 payments
  2. Honoraria $36,867 6 payments
  3. Food and Beverage $11,562 48 payments
  4. Travel and Lodging $3,720 16 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,300 1 payment
  6. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $73,380 27 payments
  2. COOLIEF $19,042 4 payments
  3. COOLED RFA $17,825 2 payments
  4. ZTLido $13,838 2 payments
  5. Qutenza $4,755 5 payments
  6. JOURNAVX $1,085 7 payments
  7. Nimbus $682 11 payments
  8. Proclaim Family of SCS IPGs $473 1 payment
  9. INTELLIS ADAPTIVESTIM $335 2 payments
  10. Evoke SCS $169 2 payments
  11. Other $478 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. TissueTech, Inc. $1,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Anesthesiology: 322

Drug cost

$305

Median for Anesthesiology: $8,738

Branded share of claims

0%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 12 $305

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$40,746

Medicare's payments for the services billed

Medicare patients

225

Average age 69

Services billed

561

150 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 38%
Diabetes 33%
Ischemic heart disease 33%
Chronic kidney disease 22%
Osteoporosis 22%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $95
$95 — —
QULIPTA
  • AbbVie, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record